On February 25, 2020 Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare IgG mediated diseases, reported that the Company’s management team will participate in the following upcoming investor conferences (Press release, Hansa Biopharma, FEB 25, 2020, View Source [SID1234554681]):
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Cowen and Company’s 40th Annual Health Care Conference in Boston on Monday, March 2, 2020, with a presentation at 4:10 PM EST/ 22:10 CET on the same day.
The Carnegie Nordic Healthcare Seminar in Stockholm on Wednesday, March 4, 2020, with a presentation at 8:00 AM CET
A live webcast of the Cowen presentation will be available on the Events & Webcast page of the Company’s website, www.hansabiopharma.com . A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.
Calendar 2020
Feb 27-28, 2020
Road Show Cowen, Chicago/Dallas
Mar 2, 2020
Cowen Annual Health Care Conference, Boston
Mar 4, 2020
Road Show Argot, New York City
Mar 4, 2020
Carnegie Nordic Healthcare Seminar, Stockholm
Mar 26, 2020
Kempen Expert Call with Prof. Mårten Segelmark on Anti-GBM
Apr 2, 2020
Annual Report 2019
Apr 21-22, 2020
Kempen Life Sciences Conference, Amsterdam
Apr 28, 2020
Interim Report Jan-Mar 2020
May 5, 2020
Annual General Meeting
May 18, 2020
UBS Global Healthcare Conference, NYC
May 19, 2020
RBC Global Healthcare Conference, NYC
May 26, 2020
ABG Life Science Summit, Stockholm
May 27, 2020
Ökonomisk Ugebrev Life Science Conference, Copenhagen
Jul 16, 2020
Interimn Report Jan-Jul 2020
Sep 16-17, 2020
Bank of America Merill Lynch Global Healthcare Conf., London
Oct 22, 2020
Interimn Report Jan-Sep 2020
CONTACT:
For further information, please contact:
Klaus Sindahl, Head of Investor Relations
Hansa Biopharma
Mobile: +46 (0) 709-298 269
E-mail: [email protected]
Rolf Gulliksen
Head of Corporate Communications
Hansa Biopharma
Mobile: +46 (0) 733-328 634
E-mail: [email protected]
This information was brought to you by Cision View Source
View Source,c3043193